DOP2013000273A - Compuestos novedosos como inhibidores de diacilglicerol aciltransferasa - Google Patents

Compuestos novedosos como inhibidores de diacilglicerol aciltransferasa

Info

Publication number
DOP2013000273A
DOP2013000273A DO2013000273A DO2013000273A DOP2013000273A DO P2013000273 A DOP2013000273 A DO P2013000273A DO 2013000273 A DO2013000273 A DO 2013000273A DO 2013000273 A DO2013000273 A DO 2013000273A DO P2013000273 A DOP2013000273 A DO P2013000273A
Authority
DO
Dominican Republic
Prior art keywords
dgat
inhibitors
diacilglicerol
aciltransferasa
new compounds
Prior art date
Application number
DO2013000273A
Other languages
English (en)
Spanish (es)
Inventor
Hemant Joshi
Donghui Qin
Raghuram Tangirala
Rowena Christensen
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47217644&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2013000273(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of DOP2013000273A publication Critical patent/DOP2013000273A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18Aralkyl radicals
    • C07D217/20Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DO2013000273A 2011-05-20 2013-11-20 Compuestos novedosos como inhibidores de diacilglicerol aciltransferasa DOP2013000273A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1451DE2011 2011-05-20
US201161495049P 2011-06-09 2011-06-09

Publications (1)

Publication Number Publication Date
DOP2013000273A true DOP2013000273A (es) 2014-04-15

Family

ID=47217644

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2013000273A DOP2013000273A (es) 2011-05-20 2013-11-20 Compuestos novedosos como inhibidores de diacilglicerol aciltransferasa

Country Status (20)

Country Link
US (1) US9242929B2 (https=)
EP (1) EP2723332B1 (https=)
JP (1) JP5893724B2 (https=)
KR (1) KR20140033426A (https=)
CN (1) CN103687595B (https=)
AU (1) AU2012259042B2 (https=)
CA (1) CA2836666A1 (https=)
CO (1) CO6811853A2 (https=)
CR (1) CR20130603A (https=)
DO (1) DOP2013000273A (https=)
EA (1) EA023239B1 (https=)
ES (1) ES2572261T3 (https=)
IL (1) IL229487A0 (https=)
MA (1) MA35398B1 (https=)
MX (1) MX2013013565A (https=)
PE (1) PE20140618A1 (https=)
PH (1) PH12013502403A1 (https=)
SG (1) SG194976A1 (https=)
WO (1) WO2012162127A1 (https=)
ZA (1) ZA201308569B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013341115B2 (en) * 2012-11-09 2016-07-14 Glaxosmithkline Llc Novel compounds as diacylglycerol acyltransferase inhibitors
WO2014081995A1 (en) * 2012-11-23 2014-05-30 Glaxosmithkline Llc Novel compounds as diacylglycerol acyltransferase inhibitors
WO2022026380A1 (en) * 2020-07-29 2022-02-03 Board Of Regents, The University Of Texas System Urea inhibitors of micro-rna
CN111747876B (zh) * 2020-08-03 2023-05-26 万华化学集团股份有限公司 一种氧化角黄素制备虾青素的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006045209A (ja) * 2004-07-02 2006-02-16 Sankyo Co Ltd ウレア誘導体
WO2006004200A1 (ja) * 2004-07-02 2006-01-12 Sankyo Company, Limited ウレア誘導体
KR20080000652A (ko) * 2005-04-19 2008-01-02 바이엘 파마슈티칼스 코포레이션 아릴 알킬산 유도체 및 그의 용도
EP2402320A1 (en) 2006-03-31 2012-01-04 Novartis AG Anorectic agents
GB0625654D0 (en) * 2006-12-21 2007-01-31 Smithkline Beecham Corp Compounds
WO2008099221A1 (en) * 2007-02-15 2008-08-21 Prosidion Limited Amide and urea derivatives for the treatment of metabolic diseases
JP2008255024A (ja) * 2007-04-02 2008-10-23 Banyu Pharmaceut Co Ltd ビアリールアミン誘導体
US8394823B2 (en) * 2008-04-11 2013-03-12 Bristol-Myers Squibb Company Triazolopyridine compounds useful as DGAT1 inhibitors
CA2790390A1 (en) 2009-08-28 2011-03-03 Daiichi Sankyo Company, Limited Novel tetrahydroisoquinoline compounds
JP2011088889A (ja) * 2009-09-24 2011-05-06 Daiichi Sankyo Co Ltd 新規テトラヒドロイソキノリン誘導体を含有する医薬
BR112012016178A2 (pt) * 2009-12-31 2015-10-06 Piramal Healthcare Ltd inibidores de diacilglicerol aciltransferase
US8314120B2 (en) 2010-03-30 2012-11-20 Abbott Gmbh & Co. Kg Small molecule potentiators of metabotropic glutamate receptors

Also Published As

Publication number Publication date
CN103687595A (zh) 2014-03-26
EP2723332A1 (en) 2014-04-30
EA023239B1 (ru) 2016-05-31
US9242929B2 (en) 2016-01-26
EP2723332B1 (en) 2016-03-02
ES2572261T3 (es) 2016-05-31
CN103687595B (zh) 2017-05-24
KR20140033426A (ko) 2014-03-18
WO2012162127A1 (en) 2012-11-29
US20150307445A1 (en) 2015-10-29
PH12013502403A1 (en) 2018-04-11
CO6811853A2 (es) 2013-12-16
PE20140618A1 (es) 2014-06-05
SG194976A1 (en) 2013-12-30
JP5893724B2 (ja) 2016-03-23
JP2014525895A (ja) 2014-10-02
MA35398B1 (fr) 2014-09-01
CR20130603A (es) 2014-09-09
CA2836666A1 (en) 2012-11-29
AU2012259042A1 (en) 2013-04-18
MX2013013565A (es) 2014-01-08
ZA201308569B (en) 2014-07-30
EP2723332A4 (en) 2014-10-15
IL229487A0 (en) 2014-01-30
AU2012259042B2 (en) 2015-06-11
EA201391724A1 (ru) 2014-04-30

Similar Documents

Publication Publication Date Title
DOP2013000272A (es) Compuestos novedosos como inhibidores de diacilglicerol aciltransferasa
UY32919A (es) Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
BR112012032579A2 (pt) "terapia de diabetes"
ECSP13013068A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2
ECSP13013024A (es) 1,3-oxazinas como inhibidores de bace1 y/o bace2
BR112012004696B8 (pt) composto modulador da atividade de tlr, seu uso, composição farmacêutica, medicamento, kit e combinação
DK2459216T3 (da) Immunogene sammensætninger omfattende tlr-aktivitetsmodulatorer
BR112014016165A2 (pt) compostos de benzaldeído substituído e métodos para seu uso no aumento da oxigenação do tecido
BR112016017193A2 (pt) Derivados de insulina, seus usos, e composição farmacêutica
MX347471B (es) Vacunas que comprenden colesterol y cpg como moleculas portadoras-adyuvantes unicas.
BR112014012230A2 (pt) fralda de vestir descartável de tamanho pequeno
PH12016500296A1 (en) Sodium channel modulators for the treatment of pain and diabetes
BR112012032721A2 (pt) compostos heterocíclicos, sua preparação e sua aplicação terapêutica
MX2013012661A (es) Compuestos de piridazina biciclicos como inhibidores pim.
AR106364A1 (es) Derivados de insulina y sus usos médicos
BR112015006656A8 (pt) composições e métodos para o tratamento de insuficiência cardíaca em pacientes diabéticos
DOP2013000273A (es) Compuestos novedosos como inhibidores de diacilglicerol aciltransferasa
CL2010001577A1 (es) Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias.
BR112015010196A2 (pt) métodos de tratar doença do fígado
BR112015010223A2 (pt) compostos tricíclicos para o uso no tratamento e/ou controle de obesidade
BR112012028906A2 (pt) polimorfos de benzoato de alogliptina
PE20150967A1 (es) Compuestos novedosos como inhibidores de diacilglicerol aciltransferasa
MX2015001677A (es) Composicion con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patologia del sistema nervioso central, y su metodo de fabricacion.
IN2013MU01154A (https=)
IN2013MU01155A (https=)